- Home
- CRGX vs NMG Comparison
CRGX vs NMG Comparison
Compare CRGX & NMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- NMG
- Stock Information
- Founded
- CRGX 2021
- NMG 2011
- Country
- CRGX United States
- NMG Canada
- Employees
- CRGX N/A
- NMG N/A
- Industry
- CRGX
- NMG Other Metals and Minerals
- Sector
- CRGX
- NMG Basic Materials
- Exchange
- CRGX Nasdaq
- NMG Nasdaq
- Market Cap
- CRGX 213.5M
- NMG 249.7M
- IPO Year
- CRGX 2023
- NMG 2017
- Fundamental
- Price
- CRGX $4.52
- NMG $2.04
- Analyst Decision
- CRGX Hold
- NMG Strong Buy
- Analyst Count
- CRGX 7
- NMG 2
- Target Price
- CRGX $5.33
- NMG $2.58
- AVG Volume (30 Days)
- CRGX 3.0M
- NMG 167.9K
- Earning Date
- CRGX 08-11-2025
- NMG 08-13-2025
- Dividend Yield
- CRGX N/A
- NMG N/A
- EPS Growth
- CRGX N/A
- NMG N/A
- EPS
- CRGX N/A
- NMG N/A
- Revenue
- CRGX N/A
- NMG N/A
- Revenue This Year
- CRGX $57.81
- NMG N/A
- Revenue Next Year
- CRGX N/A
- NMG N/A
- P/E Ratio
- CRGX N/A
- NMG N/A
- Revenue Growth
- CRGX N/A
- NMG N/A
- 52 Week Low
- CRGX $3.00
- NMG $1.22
- 52 Week High
- CRGX $25.45
- NMG $2.58
- Technical
- Relative Strength Index (RSI)
- CRGX 54.72
- NMG 60.16
- Support Level
- CRGX $4.40
- NMG $1.69
- Resistance Level
- CRGX $4.63
- NMG $2.50
- Average True Range (ATR)
- CRGX 0.07
- NMG 0.17
- MACD
- CRGX -0.01
- NMG 0.03
- Stochastic Oscillator
- CRGX 34.29
- NMG 46.24
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.